Predictive model of achieving glycemic target with Glucokinase agonist Dorzagliatin for type 2 diabetes:based on a real world study from China

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400079946

Enrollment

Unknown

Registered

2024-01-17

Start date

2024-01-31

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

Observation group:None,only record the data for diabetes in the treatment of Dorzagliatin 75mg Bid for 12 months

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) age >=18years old 2)Type 2 diabetes,Dorzagliatin is prescribed 3)Willing to participate in the study and sign a written informed consent 4)data are complete

Exclusion criteria

Exclusion criteria: 1)Under 18 years of age; 2)Patients who are allergic to any component of Dorzagliatin tablets (Vatonin ®); 3)Have participated in a clinical trial within 30 days of taking Dorzagliatin tablets (Vatonin ®); 4)Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
HbA1c;fasting blood glucose;postprandial blood glucose;ratio of patients with target-achieved HbA1c;	—

Countries

China

Contacts

Public ContactSong zhenqiang

Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University

zsong@tmu.edu.cn+86 186 0227 6218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026